Partnerships and Licensing

The breadth of our technology and IP protection allows AuraSense Therapeutics to pursue multiple parallel partnerships with pharmaceutical/ biotechnology leaders.   AuraSense Therapeutics is currently engaged in collaborations with several pharma partners to explore the use of SNA™ platform in multiple disease-specific applications.  Areas of additional partnership interest include:

Partnership Type

Field-Specific, Exclusive Collaborations on Therapeutic Targets

Key Elements/ Revenue Sources
  • Disease-specific
  • Multiple pharma manufacturers or third parties as partners
  • Milestones and co-development revenue early in life cycle
  • Royalty arrangements later in life cycle

Impacted AuraSense Technology

Antisense Particles/ siRNA Particles/ Gene Therapies

Latest News

  • Chad Mirkin to Receive Linus Pauling Medal Award

    May 20, 2013go

  • Chad Mirkin Named Entrepreneur of the Year

    May 13, 2013go

  • Nanoparticles: The Next Big Thing in Medicine

    May 7, 2013go

  • Journal NATURE Highlights SNA Platform in "Biomedicine: The New Gold Standard"

    March 13, 2013go

  • Sergei Gryaznov PhD Joins AuraSense Therapeutics as Chief Technology Officer

    February 21, 2013go